STAMBP and melanoma: One such ligand is the orally administered small molecule ligand AP1189, which has been shown to compete for the α-MSH binding site on MC1R to reduce cytokine release by macrophages in an experimental inflammatory arthritis mouse model, but did not evoke cAMP or melanogenesis in B16-F10 melanoma cultures [47].